Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia

Blood

Volumn 125, Issue 3, 2015, Pages 492-498

  Ojha, Juhi ^a   Ayres, Jackline ^b   Secreto, Charla ^c   Tschumper, Renee ^a   Rabe, Kari ^c   Van Dyke, Daniel ^c   Slager, Susan ^c   Shanafelt, Tait ^c   Fonseca, Rafael ^a   Kay, Neil E ^c   Braggio, Esteban ^a  

^a MAYO CLINIC   (United States)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; NOTCH1 RECEPTOR; PENTOSTATIN; PROTEIN P53; RITUXIMAB; TUMOR MARKER;

ALLELE; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLONAL EVOLUTION; CONTROLLED STUDY; CONVERGENT EVOLUTION; DDX3X GENE; DEEP SEQUENCING; DISEASE COURSE; FEMALE; GENE; GENE DELETION; GENE SEQUENCE; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; INDEL MUTATION; LEUKEMIA RELAPSE; LONGITUDINAL STUDY; MULTIGENE FAMILY; MULTIPLE CYCLE TREATMENT; NONSENSE MUTATION; PRIORITY JOURNAL; SF3B1 GENE; TUMOR GENE; TUMOR VOLUME; CASE CONTROL STUDY; CHROMOSOME ABERRATION; COMPARATIVE STUDY; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR EVOLUTION; PROGNOSIS; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; FOLLOW-UP STUDIES; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LONGITUDINAL STUDIES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84961289235     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-580563     Document Type: Article

References (36)

1. Call TG, Phyliky RL, Noël P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69(4):323-328.
2. Catovsky D, Fooks J, Richards S; MRC Working Party on Leukaemia in Adults. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. Br J Haematol. 1989;72(2):141-149.
3. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999;86(12):2684-2692.
4. Dighiero G, Maloum K, Desablens B, et al; French Cooperative Group on Chronic Lymphocytic Leukemia. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338(21):1506-1514.
5. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica. 2001;86(1):8-12.
6. Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival. Haematologica. 1999;84(12):1094-1099.
7. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777-4787.
8. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progressionfree survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53.
9. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-798.
10. Hallek M, Fischer K, Fingerle-Rowson G, et al; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
11. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
12. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-1765.
13. Braggio E, Kay NE, VanWier S, et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia. 2012;26(7):1698-1701.
14. Knight SJ, Yau C, Clifford R, et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia. 2012;26(7):1564-1575.
15. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
16. Ouillette P, Saiya-Cork K, Seymour E, Li C, Shedden K, Malek SN. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res. 2013;19(11):2893-2904.
17. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-4196.
18. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
19. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405-411.
20. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
21. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
22. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
23. Cingolani P, Platts A, Wang L L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80-92.
24. Larson DE, Harris CC, Chen K, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311-317.
25. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
26. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475(7356):348-352.
27. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515-1525.
28. Brochet X, Lefranc MP, Giudicelli V. IMGT/VQUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36 (Web Server issue):W503-508.
29. Kay NE, Eckel-Passow JE, Braggio E, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010;203(2):161-168.
30. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009;69(8):3579-3588.
31. Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol. 2006;13(2):215-228.
32. Sheather SJ, Jones MC. A reliable data-based bandwidth selection method for Kernel density estimation. J R Stat Soc Ser A Stat Soc. 1991;53(3):683-690.
33. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
34. Ojha J, Secreto C, Rabe K, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression[published online ahead of print July 18, 2014]. Leukemia. 2014.
35. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.
36. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139-2147.